These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37312233)

  • 21. Multi-targeted therapy for refractory eosinophilic granulomatosis with polyangiitis characterized by intracerebral hemorrhage and cardiomyopathy: a case-based review.
    Mutoh T; Shirai T; Sato H; Fujii H; Ishii T; Harigae H
    Rheumatol Int; 2022 Nov; 42(11):2069-2076. PubMed ID: 34287685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of eosinophilic granulomatosis with polyangiitis during the clinical course of microscopic polyangiitis: A case report.
    Ide H; Shimizu T; Koike Y; Abe K; Shigematsu K; Nishihata S; Kojima K; Ichinose K; Kawakami A
    Medicine (Baltimore); 2022 Nov; 101(44):e31401. PubMed ID: 36343053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. International Consensus on ANCA Testing in Eosinophilic Granulomatosis with Polyangiitis.
    Moiseev S; Bossuyt X; Arimura Y; Blockmans D; Csernok E; Damoiseaux J; Emmi G; Flores-Suárez LF; Hellmich B; Jayne D; Jennette JC; Little MA; Mohammad AJ; Moosig F; Novikov P; Pagnoux C; Radice A; Sada KE; Segelmark M; Shoenfeld Y; Sinico RA; Specks U; Terrier B; Tzioufas AG; Vaglio A; Zhao MH; Cohen Tervaert JW;
    Am J Respir Crit Care Med; 2020 Jun; ():. PubMed ID: 32584187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy.
    Faverio P; Bonaiti G; Bini F; Vaghi A; Pesci A
    Ther Clin Risk Manag; 2018; 14():2385-2396. PubMed ID: 30573961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study.
    Ueno M; Miyagawa I; Aritomi T; Kimura K; Iwata S; Hanami K; Fukuyo S; Kubo S; Miyazaki Y; Nakayamada S; Tanaka Y
    Arthritis Res Ther; 2022 Jun; 24(1):159. PubMed ID: 35768825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With Polyangiitis.
    Vultaggio A; Nencini F; Bormioli S; Vivarelli E; Dies L; Rossi O; Parronchi P; Maggi E; Matucci A
    Allergy Asthma Immunol Res; 2020 Sep; 12(5):885-893. PubMed ID: 32638567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effective treatment with mepolizumab in a patient with severe eosinophilic granulomatosis with polyangiitis complicated with small intestine perforation.
    Sato M; Yatomi M; Wakamatsu I; Uno S; Hanazato C; Masuda T; Yamaguchi K; Aoki-Saito H; Kasahara N; Miura Y; Tsurumaki H; Hara K; Koga Y; Sunaga N; Okada T; Ikota H; Hisada T; Maeno T
    Respir Med Case Rep; 2023; 43():101818. PubMed ID: 36950026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Significance of MPO-ANCA in Eosinophilic Granulomatosis With Polyangiitis: Experience From a Longitudinal Chinese Cohort.
    Liu S; Han L; Liu Y; Yang J; Zhang Y; Li M; Tian X; Zeng X; Wang L; Zhang F
    Front Immunol; 2022; 13():885198. PubMed ID: 35833130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ANCA-Associated Vasculitic Neuropathies: A Review.
    Koike H; Nishi R; Ohyama K; Morozumi S; Kawagashira Y; Furukawa S; Mouri N; Fukami Y; Iijima M; Sobue G; Katsuno M
    Neurol Ther; 2022 Mar; 11(1):21-38. PubMed ID: 35044596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Torasemide-induced Vascular Purpura in the Course of Eosinophilic Granulomatosis with Polyangiitis.
    Frątczak A; Polak K; Miziołek B; Bergler-Czop B
    Acta Dermatovenerol Croat; 2022 Sep; 30(2):116-118. PubMed ID: 36254546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis.
    Masumoto N; Oshikata C; Nakadegawa R; Motobayashi Y; Osada R; Manabe S; Kaneko T; Tsurikisawa N
    Allergy Asthma Clin Immunol; 2023 May; 19(1):40. PubMed ID: 37179316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis.
    Condreay LD; Parham LR; Qu XA; Steinfeld J; Wechsler ME; Raby BA; Yancey SW; Ghosh S
    Rheumatol Int; 2020 Aug; 40(8):1301-1307. PubMed ID: 32009195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study.
    Canzian A; Venhoff N; Urban ML; Sartorelli S; Ruppert AM; Groh M; Girszyn N; Taillé C; Maurier F; Cottin V; de Moreuil C; Germain V; Samson M; Jachiet M; Denis L; Rieu V; Smets P; Pugnet G; Deroux A; Durel CA; Aouba A; Cathébras P; Deligny C; Faguer S; Gil H; Godeau B; Lifermann F; Phin-Huynh S; Ruivard M; Bonniaud P; Puéchal X; Kahn JE; Thiel J; Dagna L; Guillevin L; Vaglio A; Emmi G; Terrier B;
    Arthritis Rheumatol; 2021 Mar; 73(3):498-503. PubMed ID: 33001543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concurrent Use of Mepolizumab and Rituximab for Eosinophilic Granulomatosis With Polyangiitis and Multisystem Involvement.
    Afiari A; Gabriel A; Gaiki MR
    Cureus; 2020 Jul; 12(7):e9242. PubMed ID: 32821588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mepolizumab as a glucocorticoid-sparing agent in eosinophilic granulomatosis with polyangiitis (EGPA): is a lower dose sufficient?
    Vergles M; Matković Z; Lalić K; Trkanjec JT; Tudorić N
    J Asthma; 2021 Dec; 58(12):1675-1679. PubMed ID: 32962455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss).
    Mohammad AJ; Hot A; Arndt F; Moosig F; Guerry MJ; Amudala N; Smith R; Sivasothy P; Guillevin L; Merkel PA; Jayne DR
    Ann Rheum Dis; 2016 Feb; 75(2):396-401. PubMed ID: 25467294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful Treatment With Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A Case Report.
    Toscano Peña A; Ali Munive A; Arevalo Y
    Cureus; 2023 May; 15(5):e38797. PubMed ID: 37303316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Journal Club Review of "Avacopan for the Treatment of ANCA-Associated Vasculitis".
    Soulsby WD
    ACR Open Rheumatol; 2022 Jul; 4(7):558-561. PubMed ID: 35167187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improvement of Chronic Rhinosinusitis and Reduction of the Myeloperoxidase-Antineutrophil Cytoplasmic Antibody Titer in a Patient with Eosinophilic Granulomatosis with Polyangiitis by Additional Mepolizumab.
    Tamechika SY; Isogai S; Maeda S; Naniwa T; Niimi A
    Case Rep Rheumatol; 2021; 2021():5561762. PubMed ID: 33859858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eosinophilic granulomatosis with polyangiitis developed after dupilumab administration in patients with eosinophilic chronic rhinosinusitis and asthma: a case report.
    Suzaki I; Tanaka A; Yanai R; Maruyama Y; Kamimura S; Hirano K; Kobayashi H
    BMC Pulm Med; 2023 Apr; 23(1):130. PubMed ID: 37076824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.